We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    cardio3
Previous Study | Return to List | Next Study

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (SHRINK)

This study is currently recruiting participants.
Verified October 2017 by Celyad (formerly named Cardio3 BioSciences)
Sponsor:
ClinicalTrials.gov Identifier:
NCT03310008
First Posted: October 16, 2017
Last Update Posted: October 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Celyad (formerly named Cardio3 BioSciences)
  Purpose

SHRINK (Standard cHemotherapy Regimen and Immunotherapy with NKR-2) is an open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells administered concurrently with a standard chemotherapy treatment (FOLFOX) in potentially resectable liver metastases from colorectal cancer.

The trial will test three dose levels. At each dose, the patients will receive three successive administrations, two weeks apart, NKR-2 cells. The study will enroll up to 36 patients (dose escalation and expansion phases).


Condition Intervention Phase
Colon Cancer Liver Metastasis Biological: NKR-2 cells Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:

Biological: NKR-2 cells The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).

Other Name: NKG2D CAR-T cells

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Celyad (formerly named Cardio3 BioSciences):

Primary Outcome Measures:
  • The occurrence of Dose Limiting Toxicities (DLT) in all patients during the study treatment until 14 days after the first NKR-2 study treatment administration [ Time Frame: up to resection (up to day 99 to day 126) ]
    DLT refers to any Grade 3 or higher toxicity or any Grade 2 or higher autoimmune toxicity that is experienced during treatment and within 14 days following the first NKR-2 dose, is new and at least possibly related to NKR-2 study treatment administered concurrently with chemotherapy

  • The objective response rate (ORR) before resection as measured by RECIST (version 1.1) [ Time Frame: up to resection (up to day 99 to day 126) ]
    The objective response rate (ORR) is defined as the sum of the proportions of patients achieving CR or PR. The occurrence of ORR before resection will be reported.


Secondary Outcome Measures:
  • The occurrence of AEs and SAEs and any toxicity corresponding to DLT definition during the study treatment until resection visit [ Time Frame: up to resection (up to day 99 to day 126) ]
    The occurrence of AEs and SAEs and any toxicity corresponding to DLT definition during the study treatment until resection visit

  • The occurrence of surgery complications and the wound healing status until 60 days after resection visit [ Time Frame: until 60 days after resection ]
    Surgery and wound healing complications experienced within the 60-day post-operative period in patients who underwent surgery will be reported as safety endpoints

  • The clinical benefit rate (CBR) before resection [ Time Frame: up to resection (up to day 99 to day 126) ]
    The clinical benefit rate (CBR) is defined as the proportion of patients achieving CR, PR or SD. The occurrence of CBR before resection will be reported.

  • The occurrence of mixed response (MR) before resection [ Time Frame: up to resection (up to day 99 to day 126) ]
    The different types of MR are defined according to the following criteria: at least 30% decrease in the longest diameter (or shortest diameter for nodal lesions) occurring in at least one target lesion recorded and measured at baseline (such response occurring in otherwise SD or PD status of the sum of diameters of target lesions and without the appearance of one or more new lesions will be classified as "MR (SD)", which corresponds to a SD with target lesion regression or "MR (PD)", which corresponds to PD with target lesion regression) and the appearance of new lesion(s) in otherwise PR status of the sum of diameters of target lesions will be classified as "MR (PR)".

  • The resection rate [ Time Frame: resection (day 99 to day 126) ]
    The presence of residual tumor following surgical resection will be assessed.

  • The occurrence of pathological response at surgery [ Time Frame: resection (day 99 to day 126) ]
    Resected specimens. will be graded according to the two grading systems by Rubbia-Brandt et al. and Blazer et al.

  • The disease-free survival (DFS) or progression-free survival (PFS) [ Time Frame: through study completion (up to month 28) ]
    The disease-free survival (DFS) is defined as the time from resection of liver metastases to recurrence of tumor or death from any cause. The progression-free survival (PFS) is defined as time from study registration in the study to the disease progression or death from any cause.

  • The event-free survival (EFS) [ Time Frame: through study completion (up to month 28) ]
    The event-free survival (EFS) is defined as the time from registration in the study to any of the following events: progression, non-resectability, local or distant recurrence, or death from any cause.

  • The overall survival (OS) [ Time Frame: through study completion (up to month 28) ]
    The overall survival (OS) is defined as the time from study registration in the study to death. If death does not occur before the patient's last study visit, then the survival will be censored at the date when patient is known to be alive.


Estimated Enrollment: 36
Actual Study Start Date: August 7, 2017
Estimated Study Completion Date: May 2021
Estimated Primary Completion Date: May 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose level 1 (escalation
The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
Biological: NKR-2 cells
The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Other Name: NKG2D CAR-T cells
Experimental: Dose level 2 (escalation)
The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
Biological: NKR-2 cells
The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Other Name: NKG2D CAR-T cells
Experimental: Dose level 3 (escalation)
The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
Biological: NKR-2 cells
The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Other Name: NKG2D CAR-T cells
Experimental: Recommended dose level (expansion)
The dose expansion arm will use the maximum tolerated dose.
Biological: NKR-2 cells
The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Other Name: NKG2D CAR-T cells

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women ≥ 18 years old at the time of signing the ICF
  2. Patients with histologically proven colorectal adenocarcinoma with potentially resectable liver metastases,
  3. No previous chemotherapy for metastatic CRC,
  4. The patient is due to receive first-line metastatic chemotherapy regimen with FOLFOX as a neoadjuvant
  5. The patient must have an ECOG performance status 0 or 1
  6. The patient must have sufficient bone marrow reserve, hepatic and renal functions

Detailed disease specific criteria exist and can be discussed with contacts listed below

Exclusion Criteria:

  1. Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis
  2. Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration
  3. Patients who are planned to receive concurrent growth factor, systemic steroid or other immunosuppressive therapy or cytotoxic agent, other than the treatment authorized per protocol
  4. Patients who underwent major surgery within 4 weeks before the planned day for the first treatment
  5. Patients with uncontrolled intercurrent illness or serious uncontrolled medical disorder
  6. Patients who have received a live vaccine within 6 weeks prior to the planned day for the first NKR 2 administration
  7. Patients with a family history of congenital or hereditary immunodeficiency
  8. Patients with history of any autoimmune disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03310008


Contacts
Contact: Luc Moriau, PhD +32 (0)10 394100 SHRINK@celyad.com
Contact: Joyce Meulemans +32 (0)10 394100 SHRINK@celyad.com

Locations
Belgium
Institut Jules Bordet Recruiting
Brussels, Belgium, 1000
Contact: Michel Dubuisson    +32 (0)2 541 31 79    michel.dubuisson@bordet.be   
Principal Investigator: Alain Hendlisz, MD         
Cliniques universitaires Saint-Luc Recruiting
Brussels, Belgium, 1200
Contact: Isabelle Beaufay    +32 (0)2 764 42 04    isabelle.beaufay@uclouvain.be   
Principal Investigator: Jean-Pascal Machiels, MD         
Grand Hôpital de Charleroi Not yet recruiting
Charleroi, Belgium, 6000
Contact: Greet Vandenberghe    +32 (0)71 10 47 08    Greet.Vandenberghe@ghdc.be   
Principal Investigator: Jean-Luc Canon, MD         
Sponsors and Collaborators
Celyad (formerly named Cardio3 BioSciences)
Investigators
Principal Investigator: Frédéric Lehmann, MD Celyad (formerly named Cardio3 BioSciences)
  More Information

Responsible Party: Celyad (formerly named Cardio3 BioSciences)
ClinicalTrials.gov Identifier: NCT03310008     History of Changes
Other Study ID Numbers: CYAD-N2T-003
First Submitted: August 2, 2017
First Posted: October 16, 2017
Last Update Posted: October 16, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases